SNPX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	6 874.00
Gjennomsnittsvolum	49 649.00
Markedsverdi	4.92M
EPS	$0 ( 2024-04-02 )
Neste inntjeningsdato	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.150
ATR14	$0.0710 (1.57%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Singer William S.	Buy	800	Stock Option (Right to Buy)
2024-04-08	Silverman Joshua	Buy	800	Stock Option (Right to Buy)
2024-04-08	Schechter Jonathan	Buy	800	Stock Option (Right to Buy)
2024-04-08	Bernstein Bruce	Buy	800	Stock Option (Right to Buy)
2023-03-29	Schechter Jonathan	Buy	20 000	Stock Option (Right to Buy)

INSIDER POWER
74.96
Last 71 transactions
Buy: 1 845 200 \| Sell: 283 116

Synaptogenix, Inc. Korrelasjon

10 Mest positive korrelasjoner
GOSS	0.958
VORB	0.946
BCAB	0.946
THTX	0.944
XFOR	0.943
FATE	0.942
NVTSW	0.941
RIVN	0.939
NCBS	0.938
ISPO	0.938

10 Mest negative korrelasjoner
NWLI	-0.967
AMYT	-0.967
EZGO	-0.959
RXDX	-0.956
TACO	-0.956
MLCO	-0.955
LUNA	-0.954
HZNP	-0.953
EXAS	-0.953
MLVF	-0.953

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Synaptogenix, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-6 347.00 (0.00 %)
EPS:	$-12.96

FY	2023
Omsetning:	$0
Bruttogevinst:	$-6 347.00 (0.00 %)
EPS:	$-12.96

FY	2022
Omsetning:	$0
Bruttogevinst:	$-5 714.00 (0.00 %)
EPS:	$-0.780

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.51

Financial Reports:

No articles found.

Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.